Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

INNOVATION TOOLS FOR THE MOLECULAR DIAGNOSIS OF CANCER

Award Number: R43CA105622
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 03/01/2004
PERIOD OF PERFORMANCE END DATE: 02/28/2005

Group Awards By:

View Award Description

INNOVATION TOOLS FOR THE MOLECULAR DIAGNOSIS OF CANCER - DESCRIPTION (provided by applicant): Current treatment of cancer patients relies on establishing an accurate diagnosis using a complex combination of clinical and histopathological data but in some instances accurate diagnosis is difficult or impossible because of atypical clinical or histopathological data. The National Cancer Institute has called for accurate, practical, and affordable tools for the diagnosis of cancer in both research and clinical applications. The detection, identification, and evaluation of the expression pattern of a particular mRNA across many RNA samples are becoming a powerful technique for cancer diagnosis. Molecular assay of gene expression can offer systematic human cancer information useful to make clinical judgments regarding the disease and appropriate treatments. Measurement of tumor gene expression signatures will be done with a book-sized electro-analytical instrument and a disposable 96-sensor array element. The proposed expression analysis system will perform sensitive and selective gene probe assays linked to signal amplification via electroactive enzyme labels. The anticipated Phase I result will be establishing the feasibility of this technology by accomplishing the measurable milestones of validated measurements (greater than 90% agreement with real-time PCR), capable of probing expression signatures with highly sensitive DNA sensors (milestone 10x current sensitivity of 60,000 molecules) in Electrochemical Sensor Plate assays for multiple genes or multiple samples that take less than 2 hours. Alderon Biosciences, Inc. is an innovator in the rapidly developing field of molecular detection systems and the company maintains a chemistry, biochemistry, cell culture, and engineering staff experienced with electrochemical instruments and biologically modified sensors. The company has successfully raised several million dollars in non-SBIR funding for product development, regulatory approval, and commercialization. These experiences have yielded several products including an FDA-approved in vitro-diagnostic device designed to screen children for lead poisoning.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2004 ( Subtotal = $96,608 )
2004	2004	ALDERON BIOSCIENCES INC	2810 MERIDIAN PARKWAY STE 152	DURHAM	NC	27713	DURHAM	USA	Cancer Detection and Diagnosis Research	000	1	2/27/2004	NEW	$96,608
														Subtotal = $96,608

Grand Total All Awards = $96,608

Top

All Categories

About

Search

Reports

Data Submission

Award Information

INNOVATION TOOLS FOR THE MOLECULAR DIAGNOSIS OF CANCER

Award Number: R43CA105622

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 03/01/2004

PERIOD OF PERFORMANCE END DATE: 02/28/2005

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer